Drug intelligence / Profile preview

apx-311

Development stage: Unknown
Lead developer: Aptabio Therapeutics
Modality: Small Molecules

Overview

APX-311 is a small molecule drug developed by AptaBio Therapeutics (also referred to as AptaBio Co., Ltd.) for the treatment of nonalcoholic steatohepatitis (NASH). It acts as a NOX (NADPH oxidase) inhibitor, targeting oxidative stress and inflammation pathways implicated in liver disease. The drug is considered a first-in-class hepatoprotectant with a novel mechanism of action distinct from other NASH candidates. Clinical development has progressed through Phase I trials in South Korea, with plans for Phase II trials[1][2][9].

Targets

NOX4 (NADPH oxidase 4)

Beyond the preview

Go deeper on apx-311.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on apx-311.

Explore the full profile